Latest Headlines

Latest Headlines

Sun Pharma buys GSK's Tasmania opiates business to expand pain offerings

India's top drugmaker, Sun Pharmaceutical Industries, has agreed to buy GlaxoSmithKline's opiates business in Australia, placing it as one of three owners that control the crop and production in Tasmania that is the world's largest legal supplier of pharmaceutical-grade opiates for painkillers.

Another Turkish man sentenced for smuggling fake cancer drugs into U.S.

With the sentencing of a second man from Turkey, federal authorities have essentially brought to a close a case stemming from the appearance in the U.S. of counterfeit and unapproved cancer drugs. The drugs were sold to wholesalers and physician practices throughout the U.S., in some cases making patients ill.

Turkey's drugmakers expand manufacturing as market booms

Turkey is a fast-growing market expected to be worth about $22.8 billion by the end of 2015. Domestic drugmakers, along with Big Pharma, are expanding manufacturing there to keep up with demand.

Covidien sets sights on Turkey with latest training outpost

Continuing its years-long effort to expand in emerging markets, Covidien has cut the ribbon on training center in Turkey, planning to educate local clinicians and amp up the demand for its products in the country.

Medtronic buys out a distributor as it cozies up to Turkey

Medtronic is looking to bypass some middlemen in its Turkish operation, buying a controlling stake in one of its distributors and launching a joint venture as it works to expand its share of the growing medical device market.

Turkey's Sanovel joins the emerging-markets deal buffet

The emerging-markets deals just keep popping up. Now, it's a Turkish drugmaker on the block, in a buyout that could be worth $1 billion.

ClinTec plots Turkish expansion

U.K. CRO ClinTec International has its sites set on Turkey, planning to open an office in Istanbul to tap the growing demand for clinical research in the Middle East.

Turkey eyes a $23B pharma sector by 2023, up from $5B

Turkish officials are psyched up for a big leap in its pharmaceutical business. According to a Pricewaterhouse Coopers report commissioned by the Turkish pharma industry, drug sales are poised to grow to $23.3 billion by 2023, up from $5 billion last year--provided the government makes some key moves.

Sanofi, Otsuka amp up their Turkish ambitions

Turkey's pharma market isn't as high-profile as the oft-celebrated China or India. But that doesn't mean foreign drugmakers aren't looking for ways to beef up their operations in the country.

M&A in Turkey, Indonesia underscore emerging-markets lure

Given the measly growth projections for U.S. and Europe, it's no surprise that expansion-minded drugmakers are looking eastward.